Bladder Cancer Coverage from Every Angle

Thomas Powles, MD, PhD, on Enfortumab Vedotin-ejfv: New Standard of Care for Aggressive Urothelial Carcinoma?

Posted: Monday, February 22, 2021

Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, talks about why enfortumab vedotin may become a new standard of care for patients with advanced bladder cancer. Although this agent is currently indicated for treatment in the third line after chemotherapy and immunotherapy, the EV-301 study’s head-to-head comparison of enfortumab vedotin with chemotherapy might change the therapeutic landscape.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.